WHO Essential Medicine EML section: Medicines affecting coagulation
This is information only, not a prescription. Talk to a doctor or pharmacist before taking any medicine. For an overdose or poisoning, call 102.
THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis.
Emicizumab is used for: is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. Common side effects include: The following serious adverse reactions are described elsewhere in the labeling: Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC Thromboembolism Associated with HEMLIBRA and aPCC Most common adverse reactions (incidence ≥ 10%) are injection site reactions, headache, and arthralgia.. What it is used for: is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. generated by SI from cited sources · general information, not a diagnosis · consult a health professional
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
Nepal brand names not included: no licence-safe source.
is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.
The following serious adverse reactions are described elsewhere in the labeling: Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC Thromboembolism Associated with HEMLIBRA and aPCC Most common adverse reactions (incidence ≥ 10%) are injection site reactions, headache, and arthralgia.
None. None
Pregnancy (label summary): Risk Summary There are no available data on HEMLIBRA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Animal reproduction studies have not been conducted with emicizumab-kxwh.
For a suspected overdose or poisoning, call 102 now and go to the nearest emergency hospital.
Call 102What is Emicizumab used for?
is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
How does Emicizumab work?
HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.
What are the side effects of Emicizumab?
The following serious adverse reactions are described elsewhere in the labeling: Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC Thromboembolism Associated with HEMLIBRA and aPCC Most common adverse reactions (incidence ≥ 10%) are injection site reactions, headache, and arthralgia.
Who should not take Emicizumab?
None. None
Does Emicizumab have a boxed warning?
THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis.
Can I take Emicizumab in pregnancy or while breastfeeding?
Pregnancy (label summary): Risk Summary There are no available data on HEMLIBRA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Animal reproduction studies have not been conducted with emicizumab-kxwh.
What is the dose of Emicizumab?
Not provided here. Ask a doctor or pharmacist.
What is Emicizumab?
Emicizumab is used for: is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. Common side effects include: The following serious …
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
US FDA DailyMed; NLM RxNorm